| Auryxia (ferric citrate) / Akebia Therap |
| Active, not recruiting | 4 | 30 | US | Ferric Citrate, Auryxia | Sreedhar Mandayam, Keryx Biopharmaceuticals | End Stage Renal Disease, Chronic Kidney Diseases | 09/19 | 02/20 | | |
NCT04485039: Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders |
|
|
| Completed | 4 | 44 | US | Tecovirimat, TPOXX, sevelamer carbonate oral tablet, Renvela, sucroferric oxyhydroxide chewable tablet, Velphoro, calcium acetate oral tablet, PhosLo, Lanthanum Carbonate Chewable Tablet, Fosrenol | SIGA Technologies, Biomedical Advanced Research and Development Authority, PPD DEVELOPMENT, LP | Smallpox | 12/22 | 04/23 | | |
ChiCTR2400083534: Efficacy and Safety of Ferric Citrate in Chinese Hyperphosphatemia Patients Receiving Maintenance Hemodialysis: a Multicenter, Randomized, Open-label, Active-controlled Trial |
|
|
| Completed | 3 | 239 | | Taking ferric citrate tablets according to clinical trial protocols.; Taking comparison tablets according to clinical trial protocols. | Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.; Sinomune Pharmaceutical Co., Ltd, Sponsor | Hyperphosphatemia in hemodialysis patients with chronic kidney disease (CKD) | | | | |
NCT04543812: PBF-1681 (Ferric Citrate) for the Treatment of IDA in Patients With NDD-CKD |
|
|
| Completed | 3 | 141 | RoW | Ferric citrate, Placebo | Panion & BF Biotech Inc. | Anemia of Chronic Kidney Disease | 10/22 | 12/22 | | |
FRONTIER, NCT05085275: Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease |
|
|
| Completed | 3 | 289 | US | Ferric Citrate 1 GM Oral Tablet [AURYXIA], Auryxia, Placebo | USRC Kidney Research, Akebia Therapeutics | Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron | 01/24 | 01/24 | | |
NCT04523727: Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyperphosphatemia Related to Chronic Kidney Disease |
|
|
| Recruiting | 3 | 45 | US | ferric citrate, KRX-0502 | Keryx Biopharmaceuticals | Hyperphosphatemia Related to Chronic Kidney Disease | 01/25 | 06/25 | | |
NCT04649411: Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease |
|
|
| Not yet recruiting | 3 | 36 | NA | ferric citrate, KRX-0502, standard of care | Keryx Biopharmaceuticals | Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease | 01/27 | 03/27 | | |
| Recruiting | 2 | 160 | Canada, US | Ferric Citrate, Auryxia, Placebo | University of California, Los Angeles, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Chronic Kidney Diseases | 12/25 | 12/25 | | |
| Recruiting | N/A | 100 | RoW | the low-dose group (1.5 g/day) or the standard-dose group (4 g/day) | Kyowa Kirin Korea Co., Ltd. | Hyperphosphatemia | 12/25 | 12/25 | | |
NCT06186934: Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients |
|
|
| Recruiting | N/A | 600 | RoW | the standard-dose group (4 g/day) | Kyowa Kirin Korea Co., Ltd. | Hyperphosphatemia | 01/26 | 01/26 | | |
